ProfileGDS5678 / 1447203_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 29% 30% 28% 29% 42% 28% 29% 29% 29% 29% 28% 28% 29% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6794728
GSM967853U87-EV human glioblastoma xenograft - Control 22.657129
GSM967854U87-EV human glioblastoma xenograft - Control 32.6789730
GSM967855U87-EV human glioblastoma xenograft - Control 42.5827428
GSM967856U87-EV human glioblastoma xenograft - Control 52.6060129
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0715142
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.67428
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6405629
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6304429
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6545129
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6417529
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6101928
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.650328
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6483629